714 / 1835
0
25
50
75
100
Cumulative Percentage
90
Y-ibritumomab
Control
207
202
110
149
N
F
PFS From Time of Randomization (months)
Overall PFS For Treatment Groups
90
Y-ibritumomab: n = 207
Median PFS: 49.3 mo
Control: n = 202
Median PFS: 12.6 mo
7-year overall PFS 23% in control arm compared with 47% in
90
Y-ibritumomab arm
HR = 2.09 (95% CI: 1.63 – 2.67);
P
< 0.001
90
Y-ibritumomab
Control
207
143
86
102
63
89
48
25
14
At risk:
202
0
21
42
63
84